文献速递儿科影像技术与安全PETCT

双低剂量PET/CT在儿童淋巴瘤中显著降低剂量:维持诊断、分期与疗效评估效能

Significant dose reduction employing dual-low-dose PET/CT in pediatric lymphoma: maintaining diagnostic, staging, and response-assessing efficacy.
PubMed 文献 · Eur Radiol · 2025-08-15

前瞻性纳入246例≤18岁儿童淋巴瘤患者,接受半剂量[18F]FDG(1.85±0.2 MBq/kg)全身PET/CT,分为低剂量CT组(LDCT,n=127)和超低剂量CT组(ULDCT,n=119)。ULDCT组总有效剂量显著低于LDCT组(5.6±1.9 mSv vs 9.7±3.2 mSv,p<0.001),两组图像质量可接受,诊断淋巴结病变敏感度ULDCT低于LDCT(99.0% vs 99.9%,p=0.010),特异度、AUC、结外受累诊断、分期准确率及疗效评估准确率均相似。

要点

  • 超低剂量CT组总有效剂量5.6±1.9 mSv,显著低于低剂量CT组9.7±3.2 mSv(p<0.001)。
  • 诊断淋巴结病变敏感度ULDCT 99.0% vs LDCT 99.9%(p=0.010),特异度96.0% vs 94.3%及AUC 0.978 vs 0.982相似。
  • 两组结外受累诊断AUC均>0.800,分期准确率94.6%和93.6%,疗效评估准确率97.6%和96.3%。

核心结论

  • 双低剂量全身PET/CT可在不损害图像质量和诊断效能的情况下显著降低儿童淋巴瘤患者的总有效剂量。

研究设计与样本

  • 前瞻性研究,纳入246例≤18岁儿童淋巴瘤患者(9.2±3.8岁,180例男性),使用uEXPLORER扫描仪,接受半剂量[18F]FDG(1.85±0.2 MBq/kg),分为LDCT组(n=127)和ULDCT组(n=119);病灶参考标准为病理和随访证据;已获机构审查委员会批准。

诊断标准与关键数值

  • 诊断淋巴结病变:ULDCT敏感度99.0% vs LDCT 99.9%(p=0.010),特异度96.0% vs 94.3%,AUC 0.978 vs 0.982(均p>0.05);结外受累诊断AUC均>0.800;分期准确率LDCT 94.6%、ULDCT 93.6%;疗效评估准确率LDCT 97.6%、ULDCT 96.3%。

临床应用与阅片要点

  • 双低剂量PET/CT方案是儿童淋巴瘤患者的优化影像策略,可显著降低辐射暴露,同时为诊断、分期和治疗反应评估提供足够的临床效能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the clinical efficacy of a dual-low-dose total-body PET/CT protocol in pediatric lymphoma patients, incorporating low-dose PET imaging in combination with two distinct low-dose CT acquisition strategies.

MATERIALS AND METHODS: Pediatric lymphoma patients (≤ 18 years) receiving half-dose [18F]FDG (1.85 ± 0.2 MBq/kg) were prospectively enrolled and divided into low-dose CT group (LDCT) and ultra-low-dose CT group (ULDCT) using uEXPLORER scanner. Image quality was evaluated based on subjective and objective metrics. The reference standard of lesions was confirmed with pathological and follow-up evidence. The effective dose (ED), the diagnostic efficacy for detecting lesions, and the accuracy for staging, treatment responses were compared. Institutional Review Board approval was obtained.

RESULTS: A total of 246 pediatric patients were enrolled (9.2 ± 3.8 years, 180 male). The LDCT (n = 127) and ULDCT (n = 119) had similar clinical characteristics (p > 0.05) except for male percentage (78.7% vs. 67.2%, p = 0.042). The total ED of ULDCT was significantly lower than that of LDCT (5.6 ± 1.9 mSv vs. 9.7 ± 3.2 mSv, p < 0.001). Both groups showed acceptable subject image quality and were comparable in main objective parameters. ULDCT showed a sensitivity lower than LDCT (99.0% vs. 99.9%, p = 0.010) in diagnosing lymph node lesions, while their specificity (96.0% vs. 94.3%) and area under curve (AUC, 0.978 vs. 0.982) were similar (both p > 0.05). LDCT and ULDCT were also comparable in diagnosing extranodal involvements (AUCs > 0.800), staging accuracy (94.6% and 93.6%), and response assessment accuracy (97.6% and 96.3%).

CONCLUSIONS: Dual-low-dose total-body PET/CT allowed a significant reduction in total ED without compromising imaging quality and diagnosis performance in pediatric lymphoma patients.

KEY POINTS: Question [18F]FDG PET/CT scans are crucial for pediatric lymphoma patients; however, an optimized low-dose strategy has not been achieved. Findings Dual-low-dose PET/CT demonstrated sufficient image quality and clinical efficacy in pediatric lymphoma patients, with significantly reduced radiation exposure. The total radiation dosage of the ultra-low-dose CT protocol was 5.6 ± 1.9 mSv. Clinical relevance A dual-low-dose PET/CT protocol is an optimized imaging strategy for pediatric lymphoma patients that significantly reduces radiation exposure while providing sufficient clinical efficacy for diagnosing, staging and treatment response evaluation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Huang Y, Tang S, Wang T, et al. Significant dose reduction employing dual-low-dose PET/CT in pediatric lymphoma: maintaining diagnostic, staging, and response-assessing efficacy. Eur Radiol. 2025. PMID: 40815306. doi:10.1007/s00330-025-11847-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。